NOISESaved copy
Coverage history

Assembled by NOISE.

Saved report copy

Recorded

Personalized mRNA vaccine cuts melanoma recurrence risk by over 40%

Merck and Moderna reported that their personalized mRNA vaccine reduced the risk of melanoma recurrence or death by 42 percent in a Phase 3 trial. Among 1,137 high-risk patients who had surgery to remove their tumors, those who received the vaccine alongside pembrolizumab had an 82.2 percent recurrence-free rate after about 25 months, versus 70 percent with pembrolizumab alone. The vaccine, tailored to each patient's tumor, is awaiting FDA approval.